BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bardoliwala D, Patel V, Javia A, Ghosh S, Patel A, Misra A. Nanocarriers in effective pulmonary delivery of siRNA: current approaches and challenges. Ther Deliv 2019;10:311-32. [PMID: 31116099 DOI: 10.4155/tde-2019-0012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Zoulikha M, Xiao Q, Boafo GF, Sallam MA, Chen Z, He W. Pulmonary delivery of siRNA against acute lung injury/acute respiratory distress syndrome. Acta Pharm Sin B 2022;12:600-20. [PMID: 34401226 DOI: 10.1016/j.apsb.2021.08.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
2 Cun D, Zhang C, Bera H, Yang M. Particle engineering principles and technologies for pharmaceutical biologics. Adv Drug Deliv Rev 2021;174:140-67. [PMID: 33845039 DOI: 10.1016/j.addr.2021.04.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
3 Zhang Y, Almazi JG, Ong HX, Johansen MD, Ledger S, Traini D, Hansbro PM, Kelleher AD, Ahlenstiel CL. Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract. Int J Mol Sci 2022;23:2408. [PMID: 35269550 DOI: 10.3390/ijms23052408] [Reference Citation Analysis]
4 Ray S, Bhattacharyya S, Panda P, Pandey A, Ghosal K. Advances in Pulmonary Nanomedicine for Therapeutic Management of Respiratory Diseases. In: Das MK, Pathak YV, editors. Nano Medicine and Nano Safety. Singapore: Springer; 2020. pp. 237-66. [DOI: 10.1007/978-981-15-6255-6_10] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Hussain Y, Cui JH, Khan H, Makvandi P, Alam W. Biomacromolecule-mediated pulmonary delivery of siRNA and anti-sense oligos: challenges and possible solutions. Expert Rev Mol Med 2021;23:e22. [PMID: 34906269 DOI: 10.1017/erm.2021.25] [Reference Citation Analysis]
6 Patel V, Lalani R, Vhora I, Bardoliwala D, Patel A, Ghosh S, Misra A. Co-delivery of cisplatin and siRNA through hybrid nanocarrier platform for masking resistance to chemotherapy in lung cancer. Drug Deliv and Transl Res 2021;11:2052-71. [DOI: 10.1007/s13346-020-00867-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Lu ZR, Laney VEA, Hall R, Ayat N. Environment-Responsive Lipid/siRNA Nanoparticles for Cancer Therapy. Adv Healthc Mater 2021;10:e2001294. [PMID: 33615743 DOI: 10.1002/adhm.202001294] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
8 Ghosh S, Lalani R, Patel V, Bhowmick S, Misra A. Surface engineered liposomal delivery of therapeutics across the blood brain barrier: recent advances, challenges and opportunities. Expert Opinion on Drug Delivery 2019;16:1287-311. [DOI: 10.1080/17425247.2019.1676721] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Ding L, Tang S, Wyatt TA, Knoell DL, Oupický D. Pulmonary siRNA delivery for lung disease: Review of recent progress and challenges. J Control Release 2021;330:977-91. [PMID: 33181203 DOI: 10.1016/j.jconrel.2020.11.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Bardoliwala D, Javia A, Ghosh S, Misra A, Sawant K. Formulation and clinical perspectives of inhalation-based nanocarrier delivery: a new archetype in lung cancer treatment. Ther Deliv 2021;12:397-418. [PMID: 33902294 DOI: 10.4155/tde-2020-0101] [Reference Citation Analysis]